Drug Trial Radar · NCT06087458
Phase 1/2 Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jun 21, 2023
Primary completion
Oct 2027
Study completion Jun 2028
Sponsor
- Lead sponsor
- Perceive Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Phase 1 safety study of VOY-101 is comprised of escalating dose Cohorts, followed by a Phase 2 at the recommended phase 2 dose.
Conditions
- Age-Related Macular Degeneration
- Geographic Atrophy
- Non-neovascular AMD
- Non-neovascular Age-related Macular Degeneration
Interventions
VOY-101Biological
VOY-101
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: To evaluate the safety and tolerability of a single intravitreal injection of escalating doses of VOY-101Time frame: 24 Months
- Phase 1: Change from Baseline in markers of inflammationTime frame: Baseline to Month 24
- Phase 1: Establish the recommended Phase 2 dose in subjects with Geographic Atrophy.Time frame: Month 12
- Phase 2: To evaluate the effect of VOY-101 in the study eye compared with untreated fellow eye on change in Geographic Atrophy lesion size.Time frame: 15 Months
Locations
16 sites in 3 countries. Site status is shown where the registry gives one.
Retina Macula Institute of AZ
Scottsdale, Arizona
Retina Consultants San Diego
Poway, California
Retinal Consultants Medical Group
Sacramento, California
Ophthalmic Consultants of Boston
Boston, Massachusetts
The Retina Institute
St Louis, Missouri
Mid Atlantic Retina
Cherry Hill, New Jersey
Retina Northwest
Portland, Oregon
Black Hills Regional Eye Institute
Rapid City, South Dakota
Austin Research Center for Retina
Austin, Texas
Star Retina
Fort Worth, Texas
Retina Center of Texas
Southlake, Texas
University of Utah John A. Moran Eye Center
Salt Lake City, Utah
Sydney Retina Clinic and Day Surgery
Sydney, New South Wales, Australia
Cerulea Clinical Trials
East Melbourne, Victoria, Australia
Rambam Medical Center
Haifa, Israel
Tel-Aviv Sourasky Medical Center, Ophthalmology Division
Tel Aviv, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.